We are pleased to share that a new treatment for H3 K27M-mutant diffuse midline glioma received FDA accelerated approval. This milestone is a meaningful advancement in the treatment of an ultra-rare and aggressive brain tumor, which primarily affects children and young adults.
Select Jazz to learn more about our latest news in H3 K27M-mutant diffuse midline glioma.
Select continue to proceed to the Chimerix website